Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the US Food and Drug Administration in May, eyecare professionals (ECPs) across the United States can officially begin prescribing Tryptyr to their patients, Alcon said in a press release.

In addition to the US commercial availability of Tryptyr, Alcon and its team of dry eye sales specialists, have also launched an ECP campaign focusing on the speed of rapid natural tear production with Tryptyr. The campaign features ECP tools, including videos and an interactive website along with a patient website. Additionally, Alcon recently hosted a national broadcast event for ECPs, featuring in-depth conversations surrounding this DED treatment option.

According to Alcon, the US launch will also coincide with expansive access initiatives, including a full Field Access Management team dedicated to assisting ECPs with fulfillment, and a First Fill Free trial program for eligible Tryptyr patients. In addition, Alcon said that ongoing copay support will be offered for refills for eligible patients.